“Defensive” Switch Can Make Underperforming Rx An OTC Star – Consultant
This article was originally published in The Tan Sheet
Executive Summary
A proactive approach to moving drugs from Rx to OTC status through "defensive" switching will become increasingly important as drug cost containment efforts increase, according to NCI Consulting President Susan Lavine Coleman
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning